Akouos, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 72 rows, 72 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-12-01: Reporting owner Mathers Edward T; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2022-12-01: Reporting owner Wellman Jennifer Anne; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2022-12-01: Reporting owner Wellman Jennifer Anne; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2022-12-01: Reporting owner Wellman Jennifer Anne; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-12-01 | Mathers Edward T Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −54,809 0 owned after | $0.84 exercise price | 2022-12-02 | |
| 2022-12-01 | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −40,573 0 owned after | $2.32 exercise price | 2022-12-02 | |
| 2022-12-01 | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −127,319 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −130,000 0 owned after | $5.89 exercise price | 2022-12-02 | |
| 2022-12-01 | TZIANABOS ARTHUR Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,100 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | TZIANABOS ARTHUR Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −111,561 0 owned after | $0.84 exercise price | 2022-12-02 | |
| 2022-12-01 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −165,103 0 owned after | $2.32 exercise price | 2022-12-02 | |
| 2022-12-01 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −750,676 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −380,000 0 owned after | $5.89 exercise price | 2022-12-02 | |
| 2022-12-01 | SATO VICKI L Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −26,930 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | SATO VICKI L Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −12,100 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | SATO VICKI L Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | Ramasastry Saira Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | Preston Heather Director | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | PARMAR KUSH Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −16,000 0 owned after | $4.21 exercise price | 2022-12-02 | |
| 2022-12-01 | Minegishi Sachiyo Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −150,000 0 owned after | $5.89 exercise price | 2022-12-02 | |
| 2022-12-01 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −23,727 0 owned after | $0.84 exercise price | 2022-12-02 | |
| 2022-12-01 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −55,758 0 owned after | $2.32 exercise price | 2022-12-02 | |
| 2022-12-01 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −72,747 0 owned after | $7.38 exercise price | 2022-12-02 | |
| 2022-12-01 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −90,000 0 owned after | $5.89 exercise price | 2022-12-02 | |
| 2022-06-23 | Mathers Edward T Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | Preston Heather Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | Smith Christopher M Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | TZIANABOS ARTHUR Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | SATO VICKI L Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | Ramasastry Saira Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-06-23 | PARMAR KUSH Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $4.21 exercise price | 2022-06-27 | |
| 2022-02-15 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +380,000 380,000 owned after | $5.89 exercise price | 2022-02-17 | |
| 2022-02-15 | Minegishi Sachiyo Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $5.89 exercise price | 2022-02-17 | |
| 2022-02-15 | Wellman Jennifer Anne Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,000 130,000 owned after | $5.89 exercise price | 2022-02-17 | |
| 2022-02-15 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $5.89 exercise price | 2022-02-17 | |
| 2021-06-24 | Mathers Edward T Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | PARMAR KUSH Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | Preston Heather Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | Ramasastry Saira Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | SATO VICKI L Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | Smith Christopher M Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-06-24 | TZIANABOS ARTHUR Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,000 16,000 owned after | $13.39 exercise price | 2021-06-25 | |
| 2021-02-15 | Minegishi Sachiyo Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $17.97 exercise price | 2021-02-17 | |
| 2021-02-15 | McKenna Michael John Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 70,000 owned after | $17.97 exercise price | 2021-02-17 | |
| 2021-02-15 | Wellman Jennifer Anne Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $17.97 exercise price | 2021-02-17 | |
| 2021-02-15 | Robinson Gregory Scott Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $17.97 exercise price | 2021-02-17 | |
| 2021-02-15 | Simons Emmanuel Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $17.97 exercise price | 2021-02-17 | |
| 2020-10-15 holding as of filing | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $0.84 exercise price | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-10-15 | ||
| 2020-10-01 | Minegishi Sachiyo Officer (CHIEF FINANCIAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +257,780 257,780 owned after | $22.45 exercise price | 2020-10-15 | |
| 2020-10-01 | Wellman Jennifer Anne Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $22.45 exercise price | 2020-10-15 | |
| 2020-10-01 | McKenna Michael John Officer (CHIEF MEDICAL OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $22.45 exercise price | 2020-10-05 | |
| 2020-10-01 | Robinson Gregory Scott Officer (CHIEF SCIENTIFIC OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $22.45 exercise price | 2020-10-05 | |
| 2020-06-26 | Simons Emmanuel Director, Officer (President & CEO) | 4/A | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +145,095 145,095 owned after | $17.00 exercise price | 2020-07-22 | |
| 2020-06-26 | Simons Emmanuel Director, Officer (President and CEO), 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +838,066 838,066 owned after | $17.00 exercise price | 2020-06-30 | |
| 2020-06-26 | Ramasastry Saira Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,625 22,625 owned after | $17.00 exercise price | 2020-06-30 | |
| 2020-06-25 holding as of filing | Simons Emmanuel Director, Officer (President & CEO), 10% Owner | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $0.85 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Simons Emmanuel Director, Officer (President & CEO), 10% Owner | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Simons Emmanuel Director, Officer (President & CEO), 10% Owner | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | McKenna Michael John Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $0.85 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | McKenna Michael John Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | McKenna Michael John Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Ozden Rabia Gurses Officer (Chief Development Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Ozden Rabia Gurses Officer (Chief Development Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Ozden Rabia Gurses Officer (Chief Development Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Robinson Gregory Scott Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $1.69 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Robinson Gregory Scott Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Robinson Gregory Scott Officer (Chief Scientific Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | TZIANABOS ARTHUR Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Smith Christopher M Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $2.32 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | Smith Christopher M Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | SATO VICKI L Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 | ||
| 2020-06-25 holding as of filing | SATO VICKI L Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.38 exercise price | 2020-06-25 |